Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2021 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

--NDA for Oral Sulopenem has PDUFA date of July 25, 2021-- --Cash Runway into First Half of 2023— --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 12,...
March 05, 2021 17:30 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021

DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 19, 2021 17:30 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Present in Upcoming Investor Conferences

DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 10, 2021 18:40 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares

DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 09, 2021 23:58 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 03, 2021 23:35 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 03, 2021 17:51 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 01, 2021 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch

DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
January 25, 2021 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 -- DUBLIN, Ireland and CHICAGO, Jan. 25, 2021 ...
January 06, 2021 17:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference

DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right